Catheter Precision (VTAK) CFO awarded options for 40,000 shares at $1.15

Rhea-AI Filing Summary

Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.

The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ANDERSON PHILIP J

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Options (Right to Buy) — 40,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 40,000 options Exercise price: $1.15 per share Expiration date: March 26, 2036 +2 more

5 metrics

Option grant size 40,000 options Right to buy 40,000 shares of common stock

Exercise price $1.15 per share Strike price for the stock options

Expiration date March 26, 2036 Options expiration

Vesting schedule 100% after 180 days Vests on 180-day anniversary of grant date

Total derivatives after grant 40,000 options Total options held following transaction

Key Terms

Options (Right to Buy), Grant, award, or other acquisition, exercise price, vest 100% on 180 day anniversary

4 terms

Options (Right to Buy) financial

"security_title: "Options (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "1.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest 100% on 180 day anniversary financial

"Options vest 100% on 180 day anniversary of grant date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ANDERSON PHILIP J

(Last) (First) (Middle)

1670 HIGHWAY 160 WEST SUITE 205

(Street)

FORT MILL SOUTH CAROLINA 29708

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.15	03/26/2026		A		40,000		(1)	03/26/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. Options vest 100% on 180 day anniversary of grant date.

	/s/ Philip Anderson	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Catheter Precision (VTAK) report for its CFO?

Catheter Precision reported that CFO Philip J. Anderson received a grant of stock options for 40,000 shares. These options give him the right to buy common stock at a fixed price as part of his compensation package, rather than reflecting an open-market purchase or sale.

How many Catheter Precision (VTAK) shares are covered by the CFO’s new options?

The new option grant to the CFO covers 40,000 shares of Catheter Precision common stock. This represents the number of shares he may purchase under the options once they vest and are exercisable, subject to the terms and conditions of the award agreement.

What is the exercise price of the CFO’s Catheter Precision (VTAK) stock options?

The exercise price of the CFO’s options is set at $1.15 per share. This means he can buy Catheter Precision common stock at $1.15 for each optioned share once the options vest and before they reach their stated expiration date.

When do the CFO’s Catheter Precision (VTAK) options vest and expire?

The options vest 100% on the 180-day anniversary of the grant date and expire on March 26, 2036. Full vesting after 180 days means the entire 40,000-share grant becomes exercisable at once, assuming continued service through that vesting date.

Is the Catheter Precision (VTAK) CFO’s Form 4 transaction a market buy or sell?

The Form 4 shows a grant or award acquisition, not a market buy or sell. The CFO received options at no cash cost on the transaction date, giving him the right to purchase 40,000 shares later rather than immediately trading in the open market.

How many derivative securities does the Catheter Precision (VTAK) CFO hold after this grant?

After the reported grant, the CFO holds stock options for 40,000 underlying shares. This figure reflects his total derivative position from this award as shown in the filing and indicates the maximum number of shares covered by this specific option grant.